Concepedia

Author

Stefania Salvagni

IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

Also Known As

P Maione, S SALVAGNI, S Salvagni, S. Salvagni, Silvia Novello, Stefania Salvagni

84

Publications

3.3K

Citations

28

H-Index

38

Concepts

All Affiliations

IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaUniversity of ParmaFondazione IRCCS Istituto Nazionale dei TumoriIstituti di Ricovero e Cura a Carattere ScientificoHumanitas University
SS

About

Stefania Salvagni is an author at IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola specializing in radiation oncology, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

1K

2

Health Sciences

4

4

818

3

Hepatology

3

3

734

4

Cell Biology

1

1

45

5

Gastroenterology

1

1

16

Stefania Salvagni

×

29

Publications

2.7K

Citations

24

H-Index

YearCitations

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath,

The Lancet Oncology

2012

549

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Neal Ready, Patrick A. Ott, Matthew D. Hellmann,

Journal of Thoracic Oncology

2019

319

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Luca Gianni, Anna Lladó, Giulia Bianchi,

Journal of Clinical Oncology

2010

266

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Javier Cortés, P. Fumoleau, Giulia Bianchi,

Journal of Clinical Oncology

2012

245

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Tiziana Pressiani, C. Boni, Lorenza Rimassa,

Annals of Oncology

2012

149

Pain outcomes in patients with advanced breast cancer and bone metastases

Charles S. Cleeland, Jean‐Jacques Body, Alison Stopeck,

Cancer

2012

147

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

Giulia Bianchi, Sibylle Loibl, Claudio Zamagni,

Anti-Cancer Drugs

2009

112

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study

Salvatore Siena, Lucio Crinò, Marco Danova,

Annals of Oncology

2009

98

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

Matthew D. Hellmann, Patrick A. Ott, Jon Zugazagoitia,

Journal of Clinical Oncology

2017

84

High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

Stefano Cascinu, Mario Scartozzi, Roberto Labianca,

British Journal of Cancer

2004

69

Page 1